Pharmacokinetic analysis of melphalan after superselective ophthalmic artery infusion in preclinical models and retinoblastoma patients

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 7, 2012, Pages 4205-4212

  Schaiquevich, Paula ^a   Buitrago, Emiliano ^b   Taich, Paula ^a   Torbidoni, Ana ^c   Ceciliano, Alejandro ^c   Fandino, Adriana ^c   Asprea, Marcelo ^a   Requejo, Flavio ^c   Abramson, David H ^d   Bramuglia, Guillermo F ^b   Chantada, Guillermo L ^c  

^a HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c Hematology Service   (Argentina)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERIOLAN; MELPHALAN; TOPOTECAN; UNCLASSIFIED DRUG; ALKYLATING AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CELL SURVIVAL; CELL VIABILITY; CHILD; CONTROLLED STUDY; CYTOTOXICITY; DRUG ADMINISTRATION ROUTE; DRUG DOSE REDUCTION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IC 50; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHUMAN; ORBIT EDEMA; PRESCHOOL CHILD; PRIORITY JOURNAL; RETINOBLASTOMA; SCHOOL CHILD; SUPERSELECTIVE OPHTHALMIC ARTERY INFUSION; SWINE; ANIMAL; COMPARATIVE STUDY; EXPERIMENTAL NEOPLASM; INFANT; INTRAARTERIAL DRUG ADMINISTRATION; METABOLISM; OPHTHALMIC ARTERY; PATHOLOGY; RETINA TUMOR; TUMOR CELL LINE; VITREOUS BODY;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFUSIONS, INTRA-ARTERIAL; MALE; MELPHALAN; NEOPLASMS, EXPERIMENTAL; OPHTHALMIC ARTERY; RETINAL NEOPLASMS; RETINOBLASTOMA; SWINE; VITREOUS BODY;

EID: 84866274933     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-9501     Document Type: Article

References (32)

1. Gobin YP, Dunkel IJ, Marr BP, Brodie SE, Abramson DH. Intraarterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthalmol. 2011;129:732-737.
2. Abramson DH. Chemosurgery for retinoblastoma: what we know after 5 years. Arch Ophthalmol. 2011;129:1492-1494.
3. Inomata M, Kaneko A. Chemosensitivity profiles of primary and cultured human retinoblastoma cells in a human tumor clonogenic assay. Jpn J Cancer Res. 1987;78:858-868.
4. Schaiquevich P, Buitrago E, Ceciliano A, et al. Pharmacokinetic analysis of topotecan after superselective ophthalmic artery infusion and periocular administration in a porcine model. Retina. 2011;32:387-395.
5. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440-446.
6. Carcaboso AM, Chiappetta DA, Opezzo JA, et al. Episcleral implants for topotecan delivery to the posterior segment of the eye. Invest Ophthalmol Vis Sci. 2010;51:2126-2134.
7. Norda A, Loos U, Sastry M, Goehl J, Hohenberger W. Pharmacokinetics of melphalan in isolated limb perfusion. Cancer Chemother Pharmacol. 1999;43:35-42.
8. Abramson DH, Dunkel IJ, Brodie SE, Marr B, Gobin YP. Bilateral superselective ophthalmic artery chemotherapy for bilateral retinoblastoma: tandem therapy. Arch Ophthalmol. 2010;128: 370-372.
9. Common Terminology Criteria for Adverse Events (CTCAE, v4.0, June 14, 2010). National Institutes of Health, National Cancer Institute 2009. Available at: http://www.meddramsso.com. Accessed November 19, 2011.
10. Kuhn E, Lavielle M. Maximum likelihood estimation in nonlinear mixed effects models. Comput Statist Data Anal. 2005;49:1020-1038.
11. Gouyette A, Hartmann O, Pico JL. Pharmacokinetics of highdose melphalan in children and adults. Cancer Chemother Pharmacol. 1986;16:184-189.
12. Nath CE, Shaw PJ, Montgomery K, Earl JW. Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipients. Br J Clin Pharmacol. 2007;64:151-164.
13. Minor DR, Allen RE, Alberts D, Peng YM, Tardelli G, Hutchinson J. A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma. Cancer. 1985;55:2638-2644.
14. Shields CL, Kaliki S, Shah SU, Bianciotto CG, Jabbour P, Shields JA. Effect of intraarterial chemotherapy on retinoblastomainduced retinal detachment. Retina. 2012;32:799-804.
15. Abramson DH, Marr BP, Dunkel IJ, et al. Intra-arterial chemotherapy for retinoblastoma in eyes with vitreous and/ or subretinal seeding: 2-year results. Br J Ophthalmol. 2012; 96:499-502.
16. Kaneko A, Suzuki S. Eye-preservation treatment of retinoblastoma with vitreous seeding. Jpn J Clin Oncol. 2003;33:601-607.
17. Hosoya K, Kyoko H, Toyooka N, et al. Evaluation of amino acidmustard transport as L-type amino acid transporter 1 (LAT1)- mediated alkylating agents. Biol Pharm Bull. 2008;31:2126-2130.
18. Wilson TW, Chan HS, Moselhy GM, Heydt DD Jr, Frey CM, Gallie BL. Penetration of chemotherapy into vitreous is increased by cryotherapy and cyclosporine in rabbits. Arch Ophthalmol. 1996;114:1390-1395.
19. Schouten-van Meeteren AY, van der Valk P, van der Linden HC, et al. Histopathologic features of retinoblastoma and its relation with in vitro drug resistance measured by means of the MTT assay. Cancer. 2001;92:2933-2940.
20. Saylors RL 3rd, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol. 2001;19:3463-3469.
21. Klaase JM, Kroon BB, Beijnen JH, van Slooten GW, van Dongen JA. Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb. Br J Cancer. 1994;70:151-153.
22. Wilson MW, Jackson JS, Phillips BX, et al. Real-time ophthalmoscopic findings of superselective intraophthalmic artery chemotherapy in a nonhuman primate model. Arch Ophthalmol. 2011;129:1458-1465.
23. Munier FL, Beck-Popovic M, Balmer A, Gaillard MC, Bovey E, Binaghi S. Occurrence of sectoral choroidal occlusive vasculopathy and retinal arteriolar embolization after superselective ophthalmic artery chemotherapy for advanced intraocular retinoblastoma. Retina. 2011;31:566-573.
24. Cattel L, Buffa E, De Simone M, et al. Melphalan monitoring during hyperthermic perfusion of isolated limb for melanoma: pharmacokinetic study and 99mTc-albumin microcolloid technique. Anticancer Res. 2001;21:2243-2248.
25. Aziz HA, Boutrid H, Murray TG, et al. Supraselective injection of intraarterial melphalan as the primary treatment for late presentation unilateral multifocal stage Vb retinoblastoma. Retina. 2010;30:S63-S65.
26. Abramson DH, Dunkel IJ, Brodie SE, Kim JW, Gobin YP. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology. 2008;115:1398-1404.
27. Luksch R, Grignani G, Fagioli F, et al. Response to melphalan in up-front investigational window therapy for patients with metastatic Ewing's family tumours. Eur J Cancer. 2007;43: 885-890.
28. Pritchard J, Cotterill SJ, Germond SM, Imeson J, de Kraker J, Jones DR. High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group. Pediatr Blood Cancer. 2005;44:348-357.
29. Hobbie WL, Ginsberg JP, Ogle SK, Carlson CA, Meadows AT. Fertility in males treated for Hodgkins disease with COPP/ABV hybrid. Pediatr Blood Cancer. 2005;44:193-196.
30. Gombos DS, Hungerford J, Abramson DH, et al. Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a factor? Ophthalmology. 2007;114:1378-1383.
31. Wahlin A, Roos G, Rudolphi O, Holm J. Melphalan-related leukemia in multiple myeloma. Acta Med Scand. 1982;211: 203-208.
32. Hartmann O, Oberlin O, Lemerle J, et al. Acute leukemia in two patients treated with high-dose melphalan and autologous marrow transplantation for malignant solid tumors. J Clin Oncol. 1984;2:1424-1425.